Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.91 |
| ▸ | TGM2 | P21980 | 1/20 | 0.66 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.63 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5738469 | 0.98 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL2875581 | 0.98 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL3694316 | 0.98 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL4857273 | 0.98 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL2876850 | 0.98 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL125577 | 0.98 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL3287016 | 0.98 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL4858734 | 0.98 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL3693087 | 0.98 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL8674198 | 0.98 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021055-A1 | Asymmetric Piperazine-Based Cationic Lipids | TRANSLATE BIO, INC. (US) | 2026-01-22 | — | — | US | disclosed |
| CN-119925624-A | Liver targeting compound and conjugate, preparation method and application thereof | 上海数因信科智能科技有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-118922409-A | Asymmetric piperazine-based cationic lipids | 翻译生物公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118103074-A | Cytotoxic targeting chimeras for CCR2 expressing cells | 葛兰素史克知识产权发展有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20230310435-A1 | HOST DEFENSE PROTEIN (HDP) MIMETICS FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT | INNOVATION PHARMACEUTICALS INC. (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2023178167-A1 | ASYMMETRIC PIPERAZINE-BASED CATIONIC LIPIDS | TRANSLATE BIO, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178167-A1 | ASYMMETRIC PIPERAZINE-BASED CATIONIC LIPIDS | TRANSLATE BIO, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-11666571-B2 | Host defense protein (HDP) mimetics for prophylaxis and/or treatment of inflammatory diseases of the gastrointestinal tract | INNOVATION PHARMACEUTICALS INC. (US) | 2023-06-06 | — | — | US | disclosed |
| CN-115475229-A | Preparation and use of active oxygen scavenger | 凯瑞康宁生物工程（武汉）有限公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-111356699-B | Preparation and use of active oxygen scavenger | 凯瑞康宁生物工程（武汉）有限公司 | 2022-08-23 | — | — | CN | disclosed |
| EP-0298135-A1 | Phenylalanine derivative and proteinase inhibitor | Okamoto, Shosuke (JP) | 1989-01-11 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| US-4719288-A | HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1988-01-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
| US-4613676-A | PEPTIDES | CIBA-GEIGY CORPORATION (US) | 1986-09-23 | — | — | US | disclosed |
| EP-0189305-A2 | Peptide derivatives | ICI AMERICAS INC. (US) | 1986-07-30 | — | — | EP | disclosed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | disclosed |
| EP-0001295-B1 | SOMATOSTATIN-LIKE CYCLOPEPTIDES, A PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR THERAPEUTICAL APPLICATION | CIBA-GEIGY AG (CH) | 1982-03-17 | — | — | EP | disclosed |
| US-4238481-A | HYPOGLYCEMIC AGENT; HYPERGLYCEMIC AGENT; ANIMAL GROWTH REGULATOR | CIBA-GEIGY CORPORATION (US) | 1980-12-09 | — | — | US | disclosed |
| EP-0001295-A2 | Somatostatin-like cyclopeptides, a process for their preparation, pharmaceutical compositions containing them, and their therapeutical application | CIBA-GEIGY AG (CH) | 1979-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666571-B2 | Host defense protein (HDP) mimetics for prophylaxis and/or treatment of inflammatory diseases of the gastrointestinal tract | FABP2, HMGB1, MASP2 | HTT 1086/4885TGM2 448/4885FOLH1 1646/4885 |
| US-20260021055-A1 | Asymmetric Piperazine-Based Cationic Lipids | SGMS2, SPTLC2, SGMS1 | HTT 2784/4885TGM2 2510/4885FOLH1 2509/4885 |
| US-20230310435-A1 | HOST DEFENSE PROTEIN (HDP) MIMETICS FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT | FABP2, HMGB1, MASP2 | HTT 1086/4885TGM2 448/4885FOLH1 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.